Rare Hematology Market Report 2026

The rare hematology market size has grown strongly in recent years. It will grow from $15.47 billion in 2025 to $16.52 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to limited availability of effective therapies, expansion of rare disease research initiatives, increasing awareness of rare blood disorders, improvements in diagnostic laboratory capabilities, growth in specialized hematology clinics.

The rare hematology market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rising investments in gene therapy development, increasing focus on precision medicine for rare diseases, expansion of newborn and carrier screening programs, growing collaboration between research institutes and pharma companies, advances in genomic sequencing technologies. Major trends in the forecast period include increasing adoption of gene and cell therapies, growing use of advanced genetic diagnostics, rising focus on personalized treatment pathways, expansion of specialized rare disease centers, enhanced integration of digital patient monitoring.

The rising prevalence of rare blood disorders is expected to drive growth in the rare hematology market in the coming years. Rare blood disorders are uncommon medical conditions that affect the production, function, or lifespan of blood cells or clotting factors, leading to anemia, bleeding disorders, or hemolysis. The prevalence of these conditions is increasing due to genetic mutations and inherited traits passed from parents to children. The rare hematology market supports this trend by offering specialized diagnostics and targeted therapies that help manage complex blood conditions, reduce complications, and improve long-term patient outcomes. For example, in March 2024, the National Institute for Health and Care Excellence, a UK-based public body, reported that in 2022 and 2023, 2,069 individuals in the UK were diagnosed with haemophilia B, including 374 with severe disease and 351 with moderate disease. Therefore, the increasing prevalence of rare blood disorders is driving the expansion of the rare hematology market.

Key companies in the rare hematology market are focusing on innovative therapies and strategic initiatives, such as multi-stakeholder advocacy councils, to address unmet medical needs, enhance patient support, and promote cross-indication solutions. Multi-stakeholder advocacy councils consist of patients, caregivers, and experts collaborating to improve care, raise awareness, and develop solutions for specific health conditions. For instance, in February 2023, Agios Pharmaceuticals Inc., a U.S.-based biopharmaceutical company, launched the Red Cell Revolution advocacy advisory council. This initiative brings together patients, caregivers, and healthcare professionals affected by rare hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. Its goals include strengthening community connections, generating published evidence, designing practical solutions, and raising awareness of shared challenges. Activities include sponsored podcasts, video content, and partnerships with organizations such as the National Organization for Rare Disorders to support health equity and education.

In August 2025, Norgine B.V., a Netherlands-based specialty pharmaceutical and consumer healthcare company, acquired Theravia for an undisclosed amount. Through this acquisition, Norgine aims to expand and strengthen its portfolio of rare disease therapies and accelerate access to treatments for patients with high unmet medical needs. Theravia Pharmaceuticals, based in France, specializes in providing treatments for rare hematology conditions.

Major companies operating in the rare hematology market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Abbvie Inc., Bayer AG, Sanofi S.A., Novartis AG, Astrazeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring LLC, Biogen Inc., Jazz Pharmaceuticals Plc, Octapharma AG, PharmaEssentia Corporation, Disc Medicine Inc., BioInvent International AB, Mustang Bio Inc., BlueSphere Bio Inc., Rallybio LLC.

North America was the largest region in the rare hematology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare hematology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare hematology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rare hematology market by increasing costs of imported laboratory reagents, genetic testing kits, biologics manufacturing equipment, and specialized diagnostic instruments. Research institutes, specialty clinics, and hospitals in North America and Europe are most affected due to reliance on imported advanced technologies, while Asia-Pacific faces cost pressures in expanding diagnostic infrastructure. These tariffs are contributing to higher treatment and testing costs and slower adoption of novel therapies. However, they are also encouraging domestic production of diagnostic kits, localized biomanufacturing, and regional research collaborations that strengthen long-term supply resilience.

The rare hematology market research report is one of a series of new reports that provides rare hematology market statistics, including rare hematology industry global market size, regional shares, competitors with a rare hematology market share, detailed rare hematology market segments, market trends and opportunities, and any further data you may need to thrive in the rare hematology industry. This rare hematology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rare hematology involves the study, diagnosis, and treatment of uncommon blood disorders, including rare anemias, clotting disorders, bone marrow failure syndromes, and rare blood cancers. These conditions often have limited treatment options and affect small patient populations. The field helps advance understanding, improve diagnosis, and develop targeted therapies to enhance patient outcomes and quality of life.

The main disease types in rare hematology include hemophilia, sickle cell disease, thalassemia, myelodysplastic syndromes, and others. Hemophilia is a genetic bleeding disorder in which the blood does not clot properly due to the deficiency or absence of certain clotting factors, resulting in excessive bleeding and difficulty stopping hemorrhages. Treatment options include gene therapy, stem cell transplantation, blood transfusions, and pharmacotherapy, supported by diagnostic techniques such as laboratory tests, blood tests, bone marrow biopsies, imaging, MRI scans, ultrasounds, genetic testing, carrier screening, and whole genome sequencing. Applications span both pediatric and adult populations, serving end-users including hospitals, specialty clinics, and research institutes.

The rare hematology market includes revenues earned by entities through genetic testing, disease monitoring, blood transfusion support, patient care management, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.